

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

August 2, 2024

R. Kirk HuntsmanChief Executive OfficerVivos Therapeutics, Inc.7921 Southpark Plaza, Suite 210Littleton, Colorado 80120

Re: Vivos Therapeutics, Inc. Registration Statement on Form S-3 Filed July 30, 2024 File No. 333-281090

Dear R. Kirk Huntsman:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Margaret Sawicki at 202-551-7153 with any questions.

Sincerely,

Division of Corporation Finance Office of Industrial Applications and Services

cc: Lawrence Rosenbloom, Esq.